Semaglutide

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4506 publications

Correction: Revisional Metabolic and Bariatric Surgery Versus Semaglutide: Which Strategy Has Greater Efficacy for Recurrent Weight Gain After Primary Bariatric Surgery?

Correction: Revisional Metabolic and Bariatric Surgery Versus Semaglutide: Which Strategy Has Greater Efficacy for Recurrent Weight Gain After Primary Bariatric Surgery?

Journal: Obesity surgery

Published: April 14, 2026

Genetic variants show link to patients losing more weight when taking Wegovy and Mounjaro.

Genetic variants show link to patients losing more weight when taking Wegovy and Mounjaro.

Journal: BMJ (Clinical research ed.)

Published: April 13, 2026

Therapeutic Efficacy, Biomarker Signatures and Translatability of Semaglutide in the Liver Biopsy-Confirmed GAN DIO-MASH Mouse Model.

Therapeutic Efficacy, Biomarker Signatures and Translatability of Semaglutide in the Liver Biopsy-Confirmed GAN DIO-MASH Mouse Model.

Journal: American journal of physiology. Gastrointestinal and liver physiology

Published: April 13, 2026

Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review.

Comparison of pharmacotherapies for obesity with sleeve gastrectomy: a network meta-analysis and systematic review.

Journal: Expert review of endocrinology & metabolism

Published: April 13, 2026

Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults.

Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults.

Journal: The Senior care pharmacist

Published: April 12, 2026

In brief: Rybelsus R2 rebranded as Ozempic.

In brief: Rybelsus R2 rebranded as Ozempic.

Journal: The Medical letter on drugs and therapeutics

Published: April 10, 2026

Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.

Semaglutide-Induced Weight Loss Is the Main Determinant for the Improvement of Hepatic Biochemistry and Elastographic Repeated Measurements with FibroScan® in Patients with Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease.

Journal: Metabolic syndrome and related disorders

Published: April 07, 2026

FDA Approves Higher-Dose Injectable Semaglutide.

FDA Approves Higher-Dose Injectable Semaglutide.

Journal: JAMA

Published: April 03, 2026

Medicare Spending Implications for Semaglutide Under Voluntary Price Agreements.

Medicare Spending Implications for Semaglutide Under Voluntary Price Agreements.

Journal: JAMA

Published: April 02, 2026

Comment on 'Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach'.

Comment on 'Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model-Informed Drug Development Approach'.

Journal: Diabetes, obesity & metabolism

Published: April 02, 2026

Fibrillar and Micellar Aggregation of Semaglutide and Formation of a Chiral-Imprinted Glass.

Fibrillar and Micellar Aggregation of Semaglutide and Formation of a Chiral-Imprinted Glass.

Journal: Biomacromolecules

Published: April 01, 2026

Semaglutide for obesity: a pill for every ill?

Semaglutide for obesity: a pill for every ill?

Journal: Archives of disease in childhood

Published: March 31, 2026

Showing 1-12 of 4,506

Last Updated: 04/28/2026